Last reviewed · How we verify
Immunoglobulin G
Immunoglobulin G is a Non-Standardized Plant Allergenic Extract [EPC] Small molecule drug developed by Green Cross Corporation. It is currently FDA-approved. Also known as: IgG, IV IgG, GCIV.
Immunoglobulin G (IgG) is a type of antibody that represents approximately 75% of serum antibodies in humans, primarily found in blood circulation. IgG molecules are created and released by plasma B cells, each having two paratopes, and are used as a replacement therapy and for their immunomodulatory effects.
At a glance
| Generic name | Immunoglobulin G |
|---|---|
| Also known as | IgG, IV IgG, GCIV |
| Sponsor | Green Cross Corporation |
| Drug class | Non-Standardized Plant Allergenic Extract [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Headache
- Nausea/Vomiting
- Fatigue
- Nasal/Sinus Congestion
- Rash
- Arthralgia
- Diarrhea
- Muscle Pain/Aches
- Infusion Site Pain/Swelling
- Abdominal Pain/Discomfort
- Cough
- Dizziness
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunoglobulin G CI brief — competitive landscape report
- Immunoglobulin G updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI
Frequently asked questions about Immunoglobulin G
What is Immunoglobulin G?
Who makes Immunoglobulin G?
Is Immunoglobulin G also known as anything else?
What drug class is Immunoglobulin G in?
What development phase is Immunoglobulin G in?
What are the side effects of Immunoglobulin G?
Related
- Drug class: All Non-Standardized Plant Allergenic Extract [EPC] drugs
- Manufacturer: Green Cross Corporation — full pipeline
- Also known as: IgG, IV IgG, GCIV
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing